Rapt Therapeutics price target raised to $60 from $41 at Clear Street

Clear Street analyst Kaveri Pohlman raised the firm’s price target on Rapt Therapeutics (RAPT) to $60 from $41 and keeps a Buy rating on the shares. The price target raise follows Rapt presenting data from the P2b CSU trial conducted by its Chinese partner, Jeyou, which revealed that “RPT904 delivered modestly superior efficacy vs. XOLAIR in the Q12W regimen,” which achieved the firm’s Bull Case 1. Clear Street believes these results “make a compelling case for the FA program.”